Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN) research hub
7 indexed studies · 0 currently recruiting
- ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
This study is testing a new medicine, BMS-986288, alone and with another drug, nivolumab. It's for people with various advanced cancers. The main goals are to check for side effects and how well the new medicine works against the cancer.
Spain · France · Italy - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors
This study is testing a new medicine, NECVAX-NEO1, alongside standard cancer treatments (like anti-PD-1 or anti-PD-L1 drugs). It's for people with certain solid tumours like lung cancer or melanoma. This early-stage trial aims to see if the new medicine is safe and how it works in the body.
Lithuania - active not recruiting
Minimal SN Tumor Burden
This study is gathering information on people with a certain type of melanoma to see if they can avoid a big surgery. We want to find out if removing fewer lymph nodes is safe for patients with very small amounts of cancer in their nodes.
Belgium · France · Germany - active not recruitingPHASE1
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
This study is testing a new drug, PF-08046049/SGN-BB228, for advanced melanoma and other difficult-to-treat solid cancers. It aims to find a safe dose and see how well it works, as well as checking for side effects.
United States · Canada · France - active not recruitingPHASE2
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
United States · France · Germany - ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor
This study is looking at a new medicine called Acasunlimab, by itself and with another drug Pembrolizumab (Keytruda), for people with an advanced skin cancer called melanoma. It’s for melanoma that has come back or spread after previous treatment with checkpoint inhibitors.
France · Spain · Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
France · Italy · Germany